Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt127PMID 23559152
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012influential reference
• Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.

  2012cited by this paper
• Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

  2012cited by this paper
• Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

  2012cited by this paper
• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  2012influential reference
• Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.

  2012cited by this paper
• Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

  2012cited by this paper
• Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.

  2012cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Integrative Genomics Viewer

  2011cited by this paper
• BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

  2011influential reference
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals

  2011cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010influential reference
• De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Understanding resistance to EGFR inhibitors—impact on future treatment strategies

  2010cited by this paper
• High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• A highly annotated whole-genome sequence of a Korean individual

  2009cited by this paper
• PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

  2009cited by this paper
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

  2009cited by this paper
• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer

  2009cited by this paper
• Alterations of the Notch pathway in lung cancer

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  2006cited by this paper
• NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis

  2006cited by this paper
• Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

  2006cited by this paper
• Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

  2006cited by this paper
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  2006cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• BH3 - only proteins: evolutionarily conserved proapoptotic Bcl - 2 family members essential for init

  2002cited by this paper

• Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC

  2025cites this paper
• Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer

  2025cites this paper
• MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

  2025cites this paper
• Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study

  2025cites this paper
• A Review of Genetic Alteration Correlated with Primary and Acquired Resistance to EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer

  2025cites this paper
• Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches

  2025cites this paper
• Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis

  2025cites this paper
• Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations

  2025cites this paper
• Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.

  2024cites this paper
• Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report

  2024cites this paper
• Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

  2023cites this paper
• Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.

  2023cites this paper
• Identification of risk factors of EGFR-TKIs primary resistance in lung adenocarcinoma patients and construction of a risk predictive model: a case-control study

  2023cites this paper
• Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer.

  2023cites this paper
• Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

  2022cites this paper
• Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non–small cell lung cancer patients

  2022cites this paper
• Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.

  2022cites this paper
• Durable clinical response to immunotherapy in EGFR-mutated lung adenocarcinoma with squamous cell carcinoma transformation and high expression of PD-L1 after resistance development: A case report

  2022cites this paper
• Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma

  2022cites this paper
• Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

  2022cites this paper
• Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.

  2022cites this paper
• Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma

  2021cites this paper
• The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report

  2021influential citation
• PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.

  2021cites this paper
• Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis

  2021cites this paper
• The Predictive Role of Sarcopenia in Lung Adenocarcinoma Patients Treated with Erlotinib

  2021cites this paper
• Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer

  2021influential citation
• PGPM_A_329055 1291..1302

  2021cites this paper
• Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

  2021influential citation
• Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

  2021cites this paper
• Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms

  2020cites this paper
• ERβ1 Expression Patterns Have Different Effects On EGFR TKIs Treatment Response in EGFR Mutant Lung Adenocarcinomas.

  2020cites this paper
• Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients

  2020cites this paper
• BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment

  2020influential citation
• Tumorspheres as an in vitro model for cancer stem-like cell characterization in non-small cell lung cancer. Prognostic implications

  2020cites this paper
• Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis

  2020cites this paper
• Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

  2020cites this paper
• Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma

  2020cites this paper
• Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

  2019cites this paper
• The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer

  2019cites this paper
• 1 Intrinsic resistance to EGFR-tyrosine kinase 2 inhibitors in EGFR-mutant non-small cell lung 3 cancer : differences and similarities with acquired 4 resistance 5

  2019influential citation
• High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.

  2019cites this paper
• Survival Implications of De Novo Versus Recurrent Metastatic Non–Small Cell Lung Cancer

  2019cites this paper
• Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.

  2019cites this paper
• BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer

  2019cites this paper
• Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy

  2019cites this paper
• Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

  2019influential citation
• De Novo HER2 S310Y mutation associates with poor response to EGFR tyrosine kinase inhibitor in activating EGFR-mutant NSCLC patient: A case report

  2019cites this paper
• EGFR-TKI原发性耐药的分子机制及其进展——附2例病例分析

  2019cites this paper
• Mutaciones del gen del receptor del factor de crecimiento epidérmico (egfr) en pacientes con carcinoma no microcítico de pulmón: cribado poblacional, significado predictivo y pronóstico y estrategias terapéuticas a la progresión

  2019cites this paper
• The Effects and Mechanisms by which Saikosaponin-D Enhances the Sensitivity of Human Non-small Cell Lung Cancer Cells to Gefitinib

  2019cites this paper
• Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.

  2019cites this paper
• Clinicopathologic Features and Immune Microenvironment of Non–Small‐cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

  2018cites this paper
• Malignant mixed ovarian germ cell tumor composed of immature teratoma, yolk sac tumor and embryonal carcinoma harboring an EGFR mutation: a case report

  2018cites this paper
• Association between BIM polymorphism and lung cancer outcomes: a meta-analysis.

  2018cites this paper
• Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib

  2018cites this paper
• BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma

  2018cites this paper
• Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

  2018cites this paper
• Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

  2018cites this paper
• Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment

  2018influential citation
• Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

  2018cites this paper
• Synthesis and Biological Evaluation of Some Novel Thiophene-bearing Quinazoline Derivatives as EGFR Inhibitors

  2018cites this paper
• Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.

  2018cites this paper
• A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer

  2018cites this paper
• Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

  2017cites this paper
• Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

  2017cites this paper
• Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer

  2017cites this paper
• ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma

  2017cites this paper
• Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer

  2017cites this paper
• New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

  2017cites this paper
• A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

  2017cites this paper
• Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

  2017cites this paper
• Inhibition of histone deacetylases sensitizes EGF receptor‐TK inhibitor‐resistant non‐small‐cell lung cancer cells to erlotinib in vitro and in vivo

  2017cites this paper
• Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

  2017cites this paper
• Primary Double‐Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

  2017cites this paper
• Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

  2017cites this paper
• Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion‐positive non–small cell lung cancer

  2017cites this paper
• 161 Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors by Transformation to Small Cell Lung Cancer in an EGFR-mutant Patient EGFR

  2017cites this paper
• Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes

  2017cites this paper
• Exploring Clinical and Genetic Factors to Optimize the Use of Tyrosine Kinase Inhibitors in Clinical Practice

  2017cites this paper
• Current status of research and treatment for non-small cell lung cancer in never-smoking females

  2017cites this paper
• EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma

  2017cites this paper
• Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations

  2017cites this paper
• Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance

  2016cites this paper
• Commentary: Ethics of Clinical Trials in Low-Resource Settings Vinay Prasad et al Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti Vincent DeGennaro et al Tuberculosis Diagnosis Delaying Treatment of Cancer

  2016cites this paper
• Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-Reply.

  2016cites this paper
• Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

  2016cites this paper
• Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma.

  2016cites this paper
• Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.

  2016cites this paper
• 自噬在EGFR-TKI类肿瘤靶向药物对肺癌的治疗和耐药中作用的研究进展

  2016cites this paper
• The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

  2016cites this paper
• Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

  2016cites this paper
• Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions

  2016cites this paper
• Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

  2016cites this paper
• The pharmacogenomics of drug resistance to protein kinase inhibitors.

  2016cites this paper
• BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

  2016cites this paper
• Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  2016cites this paper
• Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations

  2015cites this paper
• Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

  2015cites this paper
• Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.

  2015cites this paper